Field Treatment of Actinic Keratoses - Focus on COX-2-Inhibitors

Actas Dermo-Sifiliograficas

Volumn 100, Issue SUPPL. 2, 2009, Pages 55-58

  Ulrich, M ^a   Stockfleth, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

actinic keratoses; apoptosis; carcinoma in situ; COX 2; diclofenac; hyaluronic acid

Indexed keywords

DICLOFENAC; HYALURONIC ACID; PLACEBO;

ACTINIC KERATOSIS; APOPTOSIS; ARTICLE; CLINICAL TRIAL; DRY SKIN; ERYTHEMA; HUMAN; NONHUMAN; PARESTHESIA; PRURITUS; SKIN CANCER; SKIN CARCINOGENESIS; ULTRAVIOLET B RADIATION;

CYCLOOXYGENASE 2 INHIBITORS; HUMANS; KERATOSIS, ACTINIC;

EID: 76749144682     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(09)73379-4     Document Type: Article

References (38)

1. Memon A.A., Tomenson J.A., Bothwell J., and Friedmann P.S. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 142 (2000) 1154-1159
2. Salasche S.J. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 42 (2000) 4-7
3. Frost C., Williams G., and Green A. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol 115 (2000) 273-277
4. Trakatelli M., Ulrich C., del Marmol V., Euvrard S., Stockfleth E., and Abeni D. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 156 Suppl 3 (2007) 1-7
5. Stockfleth E., Ulrich C., Meyer T., and Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 160 (2002) 251-258
6. Ulrich C., Christophers E., Sterry W., Meyer T., and Stockfleth E. Skin diseases in organ transplant patients. Hautarzt 53 (2002) 524-533
7. Ackerman A.B. Solar keratosis is squamous cell carcinoma. Arch Dermatol 139 (2003) 1216-1217
8. Heaphy Jr. M.R., and Ackerman A.B. The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol 43 (2000) 138-150
9. Röwert-Huber J., Patel M.J., Forschner T., Ulrich C., Eberle J., Kerl H., et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 156 Suppl 3 (2007) 8-12
10. Park W.S., Lee H.K., Lee J.Y., Yoo N.J., Kim C.S., and Kim S.H. P53 mutations in solar keratosis. Hum Pathol 27 (1996) 1180-1184
11. Kushida Y., Miki H., and Ohmori M. Loss of herterozygosity in actinic keratosis, squamous cell carcinoma and sun-exposed normal appearing skin: difference between Japanese and Caucasians. Cancer 140 (1999) 169-175
12. Nelson M.A., Einspahr J.G., Alberts D.S., Balfour C.A., Wymer J.A., Welch K.L., et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 85 (1994) 23-29
13. Chuang T.Y., Heinrich L.A., Schultz M.D., Reizner G.T., Kumm R.C., and Cripps D.J. PUVA and skin cancer. A historical cohort study on 492 patients. J Am Acad Dermatol 26 2 Pt 1 (1992) 173-177
14. Jackson S., and Storey A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 19 (2000) 592-598
15. Jackson S., Harwood C., Thomas M., Banks L., and Storey A. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 14 (2000) 3065-3073
16. Hazard K., Karlsson A., Andersson K., Ekberg H., Dillner J., and Forslund O. Cutaneous human papillomaviruses persist on healthy skin. J Invest Dermatol 127 (2007) 116-119
17. Nindl I., Gottschling M., and Stockfleth E. Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers 23 (2007) 247-259
18. Braakhuis B.J.M., Tabor M.P., Kummer J.A., Leemans C.R., and Brakenhoff R.H. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 63 (2003) 1727-1730
19. Fecker L.F., Stockfleth E., Nindl I., Ulrich C., Forschner T., and Eberle J. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol 156 Suppl 3 (2007) 25-33
20. Eberle J., Fecker L.F., Forschner T., Ulrich C., Röwert-Huber J., and Stockfleth E. Apoptosis pathways as promising targets for skin cancer therapy. Br J Dermatol 156 Suppl 3 (2007) 18-24
21. Vane J.R., and Botting R.M. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 44 (1995) 1-10
22. Wang D., and DuBois R.N. Prostaglandins and cancer. Gut 55 (2006) 115-122
23. DuBois R.N., Abrahamson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., et al. Cyclooxygenase in biology and disease. FASEB J 12 (1998) 1063-1073
24. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular and molecular biology. Ann Rev Biochem 69 (2000) 145-182
25. Yu W., Murray N.R., Weems C., Chen L., Guo H., Ethridge R., et al. Role of Cyclooxygenase 2 in protein kinase C beta IImediated colon carcinogenesis. J Biol Chem 278 (2003) 11167-11174
26. Muller-Decker K. Cyclooxegenases in the skin. J Dtsch Dermatol Ges 2 (2004) 668-675
27. Nijsten T., Colpaert C.G., Vermeulen P.B., Harris A.L., Van Marck E., and Lambert J. Cyclooxegenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical of 35 cases. Br J Dermatol 151 (2004) 837-845
28. Johnsen J.I., Lindskog M., Ponthan F., Pettersen I., Elfman L., Orrego A., et al. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in-vivo. Cancer Res 64 (2004) 7210-7215
29. Johnsen J.I., Lindskog M., Ponthan F., Pettersen I., Elfman L., Orrego A., et al. NSAIDs in neuroblastoma therapy. Cancer Lett 228 (2005) 195-2001
30. Seed M.P., Brown J.R., Freemantle C.N., Papworth J.L., Colville-Nash P.R., Willis D., et al. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluran. Cancer Res 57 (1997) 1625-1629
31. Wang C., Tammi M., and Tammi R. Distribution of hyaluran and its CD 44 receptor in the epithelia of human skin appendages. Histochemistry 98 (1992) 105-112
32. Jain R.K. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 29 (2002) 3-9
33. Gallo O., Franchi A., Magnelli L., Sardi I., Vannacci A., Boddi V., et al. Cyclooxygenase pathway correlates with VEGF expression in head and neck cancer. Implications for tumour angiogenesis and metastasis. Neoplasia 3 (2001) 53-61
34. Rivers J.K., Arlette J., Shear N., Guenther L., Carey W., and Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2,5% hyaluronan gel. Br J Dermatol 146 (2002) 94-100
35. Gebauer K., Brown P., and Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Austr J Dermatol 44 (2003) 40-45
36. Wolf Jr. J.E., Taylor J.R., Tschen E., and Kang S. Topical 3,0% diclofenac in 2,5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 40 (2001) 709-713
37. Ulrich C., Hackethal M., Ulrich M., Howorka A., Forschner T., Sterry W., et al. Treatment of multiple actinic keratosis with topical diclofenac 3% gel (Solaraze™) in organ transplant recipients: a series of 6 cases. Br J Dermatol 156 Suppl 3 (2007) 40-42
38. Ulrich C., Forschner T., Ulrich M., Stockfleth E., Sterry W., and Termeer C. Management of actinic cheilitis using diclofenac 3% gel: a report of six cases. Br J Dermatol 156 Suppl 3 (2007) 43-46